Support your IND with
relevant human data

CANscript offers a human, immune-relevant platform that recapitulates the tumor microenvironment to secure clinically-validated response data in a heterogeneous laboratory study, including phenotypic, genomic, and mechanistic data.

You don’t need to wait for the clinic to get human data.
With CANscript, you can:

Test in a system that reflects the complexity of clinical patients as early as possible

Determine responders and non-responders to your drug

Improve your chance of clinical trial success and reduce failure rate

Making the most of first-in-human studies

One of the keys to oncology drug development success is the ability to test compounds in a relevant human model as early as possible. CANscript enables researchers to understand what happens in truly human tissue and find real-world complexity to test before moving into the clinic.

CANscript gives researchers:

  • More than a dozen indications sourced by Mitra for testing without clinical trial recruitment, including confirmation of genomic markers in responders/non-responders
  • A clinically-validated algorithm to capture confidence-building efficacy measurements
  • The ability to customize study design for the most relevant scientific question across single agent or combination performance or by endpoint



90% Clinically Validated

CANscript preserves the heterogeneity of patient tumors for relevant environment testing.

Human tumors thrive in human, immune-specific microenvironments. Modeling response or mechanistic behavior in an immune compartment or microenvironment with non-human characteristics introduces undesired heterogeneity or biology that won’t be encountered in the clinic.

By using CANscript, researchers can interrogate tumors with drug candidates in a human system outside of the clinic.

Each patient’s cancer is unique. Testing drug candidates in a system that reflects the complexity of clinical patients is critical to increasing clinical success.

See What Works – In human, and before moving to clinical trials

Optimizing Phase I clinical trial design requires extensive data on the most likely population in which a drug will secure meaningful response or clinical benefit.

Translational issues from non-human models to human trials introduces a disconnect for researchers.

CANscript uniquely provides a human system in pre-clinical studies to gather relevant, heterogeneous data earlier than ever possible to inform optimized design for first-in-human studies.

Human. Efficient. Multiplexed.

CANscript starts with a tumor sample taken either from a biopsy or surgical resection, and a blood sample from the same donor. The tissue sample is divided into fragments that preserve the heterogeneity of the tumor, including tumor cells, immune cells, and stromal components.

The parallel sections, along with the autologous plasma, are then placed into wells coated with indication and grade-matched matrix proteins, recapitulating the tumor microenvironment.

CANscript employs a series of phenotypic endpoints into an M-score, developed from a machine learning algorithm trained and tested on thousands of patients, providing an accurate prediction of clinical response for each compound of interest.

As a result, multiple therapeutic options can be weighed simultaneously and with a high degree of accuracy, allowing researchers to understand mechanism of action and to prioritize the most promising candidates for advancement into clinical trials.

Read the Poster

Nonuniform T-cell infiltration induced by PD-1 checkpoint blockade, ex-vivo, predicts distinct clinical response

Read the Paper

Predicting clinical response to anticancer drugs using an ex vivo platform that captures tumour heterogeneity

We’ll work with you every step of the way to increase your chance of clinical trial success so you won’t get lost in translation.